Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

HIV-Associated Lipodystrophy Treatment Market Size, Share & Trends Analysis Report by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, And By Segment Forecasts, 2024-2031

HIV-Associated Lipodystrophy Treatment Market Size is valued at USD 176.82 Mn in 2023 and is predicted to reach USD 239.62 Mn by the year 2031 at a 4.05% CAGR during the forecast period for 2024-2031.  HIV-associated lipodystrophy is an unfavourable side effect of antiretroviral therapy (ART). Lipodystrophy, often HIV-associated lipodystrophy, is a disease unique to HIV-positive people. Facial, gluteal, thigh, and limb subcutaneous f...

ID: 2250 180 Pages March 2024

Per-Encounter Medical Market Size, Share & Trends Analysis Report By Product Type (Consumables, Devices, Software, Services, Others), By Application (Cardiology, Orthopedics, Obstetrics/Gynecology, Ophthalmology, Gastroenterology, Others), By End-User, By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031

Per-Encounter Medical Market Size is valued at USD 121.82 Bn in 2023 and is predicted to reach USD 377.93 Bn by the year 2031 at a 15.38% CAGR during the forecast period for 2024-2031.  Per-encounter medical describes a billing model in which a healthcare practitioner charges a set amount for each patient encounter. This means the patient will always be charged the same amount for each appointment, no matter how long or complicated. ...

ID: 2253 180 Pages March 2024

Botulinum Toxin in Urology Market Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-use (Hospitals, Urology Clinics), By Region, And By Segment Forecasts, 2024-2031

Botulinum Toxin in Urology Market Size is valued at USD 948.56 Mn in 2023 and is predicted to reach USD 1,504.89 Mn by the year 2031 at a 6.05% CAGR during the forecast period for 2024-2031.  Botulinum toxin, commonly known as Botox, has found applications in the field of urology for the treatment of various medical conditions, particularly those related to the lower urinary tract. A range of significant factors drives the growth of ...

ID: 2255 180 Pages March 2024

Medical Nitrous Oxide Market Size, Share & Trends Analysis Report By Product (Gaseous State, Liquid State), By Application (Anesthesia and Pain Relief, Cryosurgery, Surgical Insufflation), By End User (Hospitals, Home Healthcare, Academic & Research Institutions), By Region, And By Segment Forecasts, 2024-2031

Medical Nitrous Oxide Market Size is valued at USD 1.76 Bn in 2023 and is predicted to reach USD 3.03 Bn by the year 2031 at a 7.22% CAGR during the forecast period for 2024-2031. Medical nitrous oxide, often known as N2O, is a colourless and odourless gas that has been utilized in medical settings for over a century. It is popularly referred to as "laughing gas" because of the euphoric effects it produces when inhaled in small doses. Nitrous ...

ID: 2329 180 Pages February 2024

iPSC Characterization Kit Market Size, Share & Trends Analysis Report By Type (Alkaline Phosphatase Staining Assay, Pluripotency Markers (Protein), Pluripotency Markers (mRNA)), By Application, By Region, And By Segment Forecasts, 2024-2031

The iPSC Characterization Kit Market Size is predicted to grow at an 15.54 % CAGR during the forecast period for 2024-2031. Key Industry Insights & Findings from the Report: The advent of the iPSC characterization kit market arose for technological innovation, regulatory support, and collaborative partnerships that propel stem cell research forward. The increasing applications in research and therapy are expected to drive this marke...

ID: 1418 180 Pages February 2024

FMS-like Tyrosine Kinase 3 Inhibitors Market Size, Share & Trends Analysis Report By Drug Type (Mideastern, Gilbertian, Sorafenib), By Therapies (Type 1 FMS, Type 2 FMS), By Region, And By Segment Forecasts, 2024-2031

The FMS-like Tyrosine Kinase 3 Inhibitors Market Size is valued at 495.07 Million in 2023 and is predicted to reach 1455.43 Million by the year 2031 at a 14.74 % CAGR during the forecast period for 2024-2031.  The effects of inhibitors have been documented in acute myeloid leukemia patients with FMS-like tyrosine kinase 3 inhibitors3 mutations, as part of the Non-Insured Health Benefits (NIHB) program. FMS-like tyrosine kinase 3...

ID: 1389 180 Pages February 2024

Global Multiple Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Product Type (Cetuximab, Nivolumab, Atezolizumab, Ramucirumab, Pembrolizumab and Others), By Indication Type, By Region, And Segment Forecasts, 2024-2031

The Global Multiple Cancer Monoclonal Antibodies Market Size is valued at 67.21 billion in 2023 and is predicted to reach 154.24 billion by the year 2031 at a 11.19% CAGR during the forecast period for 2024-2031. Cancer monoclonal antibodies are specific antibodies with identical immune cells that are clones of a single parent cell directed to specific cellular targets. Thus, monoclonal antibodies are preciously customizable due to their ...

ID: 1112 180 Pages February 2024

Bioelectric Medicine Market Size, Share & Trends Analysis Report By Product Type (Competitive Benchmarking, Implantable Bioelectric Medicine, Non-Implantable Bioelectric Medicine), By Region, And By Segment Forecasts, 2024-2031

The Bioelectric Medicine Market Size is valued at 24.08 Billion in 2023 and is predicted to reach 43.03 Billion by the year 2031 at a 7.72 % CAGR during the forecast period for 2024-2031. Bioelectric medicine is a branch of medicine that combines neurobiology, engineering science, and molecular medicine to create nerve stimulation technologies for monitoring biological parameters during treatment. The application of electrical impuls...

ID: 1379 180 Pages February 2024

Small Molecule Immunomodulators Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Colorectal, Thoracic, Orthopedic, Ophthalmology, Neurosurgery, Cardiac Surgery, Gynecology, Others), By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Others), By Region, And By Segment Forecasts, 2024-2031.

Small Molecule Immunomodulators Market Size is valued at USD 170.74 Bn in 2023 and is predicted to reach USD 270.77 Bn by the year 2031 at a 6.07% CAGR during the forecast period for 2024-2031. Small molecule immunomodulators are compounds with low molecular weights that influence the immune system. They can be immunosuppressants (e.g., corticosteroids, JAK inhibitors) or immunostimulants (e.g., TLR agonists). Examples include methotrexate for...

ID: 2307 180 Pages January 2024

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.